Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 218,356,358 papers from all fields of science
Search
Sign In
Create Free Account
AQ 0145
Known as:
AQ-0145
, AQ0145
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
5 relations
Broader (4)
Adamantane
Amidines
Histamine Antagonists
Imidazoles
analogs & derivatives
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Inhibitory effect of iodophenpropit, a selective histamine H3 antagonist, on amygdaloid kindled seizures
Chie Harada
,
Y. Fujii
,
T. Hirai
,
K. Shinomiya
,
C. Kamei
Brain Research Bulletin
2004
Corpus ID: 39738853
Review
2001
Review
2001
[Role of central histamine in amygdaloid kindled seizures].
Chiaki Kamei
,
C. Okuma
Nihon yakurigaku zasshi. Folia pharmacologica…
2001
Corpus ID: 22154020
The role of central histamine in amygdaloid kindled seizures in rats was studied. Histamine content in the amygdala was…
Expand
1997
1997
Novel histamine H3 receptor antagonists: synthesis and evaluation of formamidine and S-methylisothiourea derivatives.
Tomokazu Goto
,
H. Sakashita
,
Kazuki Muarkami
,
Masanori Sugiura
,
Takao Kondo
,
C. Fukaya
Chemical and pharmaceutical bulletin
1997
Corpus ID: 22371559
In order to obtain a new, potent and selective histamine H3 receptor antagonists, chemical modifications of thioperamide, a well…
Expand
1995
1995
AQ-0145, a newly developed histamine H3 antagonist, decreased seizure susceptibility of electrically induced convulsions in mice.
K. Murakami
,
H. Yokoyama
,
K. Onodera
,
K. Iinuma
,
T. Watanabe
Methods and Findings in Experimental and Clinical…
1995
Corpus ID: 40460083
We studied the effect of AQ-0145, a newly developed histamine H3-receptor antagonist, on electrically induced convulsions in mice…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE